Paeds · clinical-pharmacology-and-therapeutics
Medication adherence and formulation challenges
Also known as Paediatric medication adherence · Compliance and concordance in children · Palatability and taste of children's medicines · Age-appropriate paediatric formulations · Liquid, chewable and mini-tablet formulations in children
Fellowship guide to medication adherence and formulation challenges in children: why adherence is the prescriber's job, the dimensions of non-adherence (initiation, implementation, persistence), the formulation gap and palatability science, age-appropriate formulations (liquids, chewable and dispersible tablets, mini-tablets), excipient safety in neonates, the bedside assessment of adherence barriers, the stepwise formulation-and-adherence management pathway, and the regional initiatives (STEP database, paediatric investigation plans) closing the formulation gap.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A child with a chronic disease (transplant, sickle cell, epilepsy, HIV, leukaemia) has worsening disease control and adherence has never been openly assessed or quantified
- A neonate is prescribed a liquid containing benzyl alcohol, propylene glycol or ethanol as an excipient without a documented safety check
- A tablet is routinely crushed or a capsule opened for an enteral tube or a young child without confirming bioavailability, stability, or interaction with enteral feeds
- A bitter liquid is forced or withheld in a young child without trying a palatable alternative formulation, taste-masking or a swallowing technique
- Adherence is assumed from a prescription refill record without asking the child and family how they actually take the medicine
- An adolescent on a narrow-therapeutic-index medicine (immunosuppressant, anticonvulsant, contraceptive) defaults to adult independence without structured transition and adherence support
Life stages
Care settings
Clinical exam formats
Board mappings
- Pharmacology and safe prescribing
- Quality and safety of clinical care
- Communication and patient-centred care
- Learning goal: optimise adherence and age-appropriate formulations across the paediatric age range
- Chronic disease management and transition of care
- Professional practice and family-centred communication
- Professional Qualities
- Clinical Applications and pharmacology and safe prescribing
- Long Cases involving a child on long-term treatment for a chronic disease
- Short Cases on formulation choice and adherence assessment
- Communication stations on counselling families about taking medicines
- Safe prescribing and medication safety
- Managing complex health needs and long-term conditions
- Communication and partnership with children and families
- Foundation of Practice (FOP)
- Applied Knowledge in Practice (AKP)
- Communication
- History taking and management
- Child development and daily living
- General Pediatrics Content Outline — pharmacology and safe prescribing
- General Pediatrics Content Outline — chronic disease management
- Systems-based practice and medication adherence
- Systems-Based Practice 1: Patient Safety and Quality Improvement
- Patient Care: family-centred prescribing for chronic disease
- Practice-Based Learning and Improvement: assessing and improving adherence
- Interpersonal and Communication Skills: counselling families on medicines
- Medical Expert
- Collaborator
- Health Advocate
- Pediatric EPA — safe prescribing and family-centred medication management
Overview & Definition
A registrar in a paediatric nephrology clinic sees a 6-year-old renal transplant recipient whose tacrolimus levels have been bouncing unpredictably for months. The dose is correct, the family understands the diagnosis, but the child spits out the bitter liquid and the half-tablets crumble. The registrar reaches for "non-adherence" as the label. This leaf owns that moment — medication adherence and formulation challenges — and reframes it from a failing of the child into a property of the prescribing that the prescriber can fix. The broader pharmacology, off-label use and pharmacovigilance theory lives on its own leaves; this page is about the swallow, the taste and the daily reality of taking medicine as a child. [1] [6]
Hold three words apart, because examiners live in the gaps between them. Adherence is the extent to which a person's medicine-taking behaviour corresponds to the agreed recommendations; it is shared, negotiated and behavioural. Compliance is the older term that implied the patient obeys the prescriber — it is now discouraged precisely because it frames the child or family as the problem. Persistence is the length of time a patient continues to take the medicine before stopping; it is a separate dimension from day-to-day implementation. The ABC taxonomy used in adult and paediatric research separates adherence into initiation (taking the first dose), implementation (taking it as prescribed over time) and discontinuation (stopping); non-adherence can sit in any one of these. [2]
The reason this framing matters clinically is that the formulation is half of adherence. A child cannot be adherent to a tablet they cannot swallow, a liquid that makes them vomit, or a regimen so complex that no family can sustain it. Nunn and Richey's 2005 British Journal of Clinical Pharmacology paper set out the paediatric formulation gap and remains the canonical reference; it is the paper to name at viva. The rest of this page is about closing that gap at the bedside. [1] [3]
References12ShowHide
- [1]Nunn T Formulation of medicines for children. Br J Clin Pharmacol, 2005.PMID 15948931
- [2]Dean AJ A systematic review of interventions to enhance medication adherence in children and adolescents with chronic illness. Arch Dis Child, 2010.PMID 20522463
- [3]Mennella JA Optimizing oral medications for children. Clin Ther, 2008.PMID 19108800
- [4]Mennella JA The bad taste of medicines: overview of basic research on bitter taste. Clin Ther, 2013.PMID 23886820
- [5]Salunke S The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2 - the pilot version. Int J Pharm, 2013.PMID 24070789
- [6]Allegaert K Neonates need tailored drug formulations. World J Clin Pediatr, 2013.PMID 25254168
- [7]Palmeirim MS Efficacy, safety and acceptability of a new chewable formulation versus the solid tablet of mebendazole against hookworm infections in children: a randomised controlled trial. EClinicalMedicine, 2020.PMID 33150325
- [8]Haslund-Krog SS Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study-Focus on Formulation in Children. Children (Basel), 2022.PMID 36010126
- [9]Münch J, Sessler I, Bosse HM, et al. Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children. Pharmaceutics, 2023.PMID 37376177
- [10]Perez F Acceptability of Mebendazole Chewable Tablet in Children Aged 2 to 4 Years in Peru. Pharmaceutics, 2021.PMID 35056923
- [11]Saito J Drug Formulation for Pediatric Oral Antimicrobial Agents in Japan: Current Status, Prospects, and Challenges. Pediatr Infect Dis J, 2023.PMID 37343212
- [12]Edgcomb JB Medication Adherence Among Children and Adolescents with Severe Mental Illness: A Systematic Review and Meta-Analysis. J Child Adolesc Psychopharmacol, 2018.PMID 30040434